← Back to Clinical Trials
Recruiting NCT07067710

NCT07067710 The Use of Combined Motor Imagery and Action Observation to Evaluate the Influence on Functional Parameters Such as Strength, Range of Motion, Pain or Fear of Movement Among Others, in Females Breast Cancer Survivors.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07067710
Status Recruiting
Phase
Sponsor Fundacion Miguel Servet
Condition Breast Cancer Survivor
Study Type INTERVENTIONAL
Enrollment 108 participants
Start Date 2025-02-25
Primary Completion 2025-04-28

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Motor imagery combined with action observation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 108 participants in total. It began in 2025-02-25 with a primary completion date of 2025-04-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to evaluate the effectivity of the combined motor imagery and action observation therapies to improve functional parameters such as strenght, range of motion, pain or fear of movements among others in relation to upper limb in breast cancer survivors. The main question it aims to answer is: Will a combined therapy of motor imagery and action observation improve the strenght, rang of motion, pain, limb diameter and fear of movement of the upper limb in breast cancer survivor females? The participants will be part of the IM-OA23 proyect that consist on seeing some diferent videos about upper limb mobility and then they'll have to imagine the movements and to performed themselves. Researches will compare two groups (control group and intervention group) to evaluate the diferences between them.

Eligibility Criteria

Inclusion Criteria: * Female, over 18 years, have suffered breast cancer, have ended active treatments (chemotherapy, radiotherapy, surgery), have pain or functional limitation or lymphedema at upper limb afected. Exclusion Criteria: * males, people with active treatments ongoning, other types of cancer, recurrence or metastasis of cancer

Contact & Investigator

Central Contact

Pilar Arnal-Vallés, Candidate PhD

✉ pilararnal3b@gmail.com

📞 +34 948166117

Principal Investigator

Paula Escalada-Hernández, PhD

STUDY DIRECTOR

Public University of Navarra

Frequently Asked Questions

Who can join the NCT07067710 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer Survivor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07067710 currently recruiting?

Yes, NCT07067710 is actively recruiting participants. Contact the research team at pilararnal3b@gmail.com for enrollment information.

Where is the NCT07067710 trial being conducted?

This trial is being conducted at Pamplona, Spain, Pamplona, Spain, Pamplona, Spain.

Who is sponsoring the NCT07067710 clinical trial?

NCT07067710 is sponsored by Fundacion Miguel Servet. The principal investigator is Paula Escalada-Hernández, PhD at Public University of Navarra. The trial plans to enroll 108 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology